Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

The success of molecular targeted therapy in cancer may depend on the selection of appropriate tumor types whose survival depends on the drug target, so-called “oncogene addiction.” Preclinical approaches to defining drug-responsive subsets are needed if initial clinical trials are to be directed at...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Smolen, Gromoslaw A., Sordella, Raffaella, Muir, Beth, Mohapatra, Gayatry, Barmettler, Anne, Archibald, Heidi, Kim, Woo J., Okimoto, Ross A., Bell, Daphne W., Sgroi, Dennis C., Christensen, James G., Settleman, Jeffrey, Haber, Daniel A.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2006
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1413705/
https://ncbi.nlm.nih.gov/pubmed/16461907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0508776103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados